View Post

Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets

In Clinical Studies News by Barbara Jacoby

By: Brittany Lovely From: Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated continued benefit in patients with HER2-positive breast cancer who had stable, treated brain metastases at baseline, according to results from a subgroup analysis of the DESTINY-Breast01 (NCT03248492). The analysis of the central nervous system (CNS) subgroup also demonstrated a consistent safety profile when compared with the overall population. Of the 24 …